Devonian Health Group (GSD) investor relations material

Company overview and strategy

• Founded in 2015, with over $60M invested and strong Canadian government support.

• Focuses on plant-derived therapeutics targeting high unmet medical needs in inflammation and fibrosis.

• Integrated, scalable GMP manufacturing and extraction capabilities support product development.

• Experienced leadership team with backgrounds in biotech, regulatory, and capital markets.

• Holds a robust intellectual property portfolio with global protection and complex-to-copy platform patents.

Lead product: THYKAMINE™

• Plant-derived supra-molecular complex from thylakoid membranes, combining anti-inflammatory and anti-fibrotic activity.

• Targets upstream inflammatory pathways, modulates cytokines, and supports TH1/TH2 balance.

• Demonstrates superior potency versus commonly used corticosteroids in preclinical assays.

• Proprietary SUPREX™ technology preserves structural integrity and biological function.

• Analytical consistency validated with ≥98% batch concordance using HPLC-MS and NMR.

Clinical pipeline and milestones

• Dermatology: Phase II/III pediatric atopic dermatitis study approved by Health Canada; adult Phase II met primary and secondary endpoints with favorable safety.

• Radiodermatitis: Canadian CTA filed; large unmet need with no effective preventive standard of care.

• Gastroenterology: Positive Phase IIa results in ulcerative colitis with strong biomarker improvements.

• Preclinical data show robust anti-fibrotic activity in MASH, IPF, and other fibrotic disease models.

• Multiple clinical, regulatory, and platform-expansion milestones expected through 2027.